GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poseida Therapeutics Inc (NAS:PSTX) » Definitions » Beneish M-Score

PSTX (Poseida Therapeutics) Beneish M-Score : -1.88 (As of Dec. 14, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Poseida Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -1.88 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Poseida Therapeutics's Beneish M-Score or its related term are showing as below:

PSTX' s Beneish M-Score Range Over the Past 10 Years
Min: -5.11   Med: -2.29   Max: 9.89
Current: -1.88

During the past 7 years, the highest Beneish M-Score of Poseida Therapeutics was 9.89. The lowest was -5.11. And the median was -2.29.


Poseida Therapeutics Beneish M-Score Historical Data

The historical data trend for Poseida Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poseida Therapeutics Beneish M-Score Chart

Poseida Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - - - -0.21 -3.01

Poseida Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.11 -3.01 -2.70 -4.39 -1.88

Competitive Comparison of Poseida Therapeutics's Beneish M-Score

For the Biotechnology subindustry, Poseida Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Poseida Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poseida Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Poseida Therapeutics's Beneish M-Score falls into.



Poseida Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Poseida Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.561+0.528 * 1+0.404 * 1.0013+0.892 * 3.0318+0.115 * 0.8723
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.3558+4.679 * -0.192774-0.327 * 1.0137
=-1.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was $14.7 Mil.
Revenue was 71.748 + 25.973 + 28.142 + 24.995 = $150.9 Mil.
Gross Profit was 71.748 + 25.973 + 28.142 + 24.995 = $150.9 Mil.
Total Current Assets was $250.7 Mil.
Total Assets was $293.6 Mil.
Property, Plant and Equipment(Net PPE) was $36.4 Mil.
Depreciation, Depletion and Amortization(DDA) was $5.5 Mil.
Selling, General, & Admin. Expense(SGA) was $40.9 Mil.
Total Current Liabilities was $78.3 Mil.
Long-Term Debt & Capital Lease Obligation was $76.6 Mil.
Net Income was 20.235 + -31.371 + -24.274 + -25.349 = $-60.8 Mil.
Non Operating Income was 2.831 + 2.644 + 2.556 + 2.827 = $10.9 Mil.
Cash Flow from Operations was -9.594 + 38.45 + -15.135 + -28.744 = $-15.0 Mil.
Total Receivables was $8.7 Mil.
Revenue was 9.352 + 20.013 + 10.343 + 10.051 = $49.8 Mil.
Gross Profit was 9.352 + 20.013 + 10.343 + 10.051 = $49.8 Mil.
Total Current Assets was $252.7 Mil.
Total Assets was $302.3 Mil.
Property, Plant and Equipment(Net PPE) was $43.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $5.5 Mil.
Selling, General, & Admin. Expense(SGA) was $37.9 Mil.
Total Current Liabilities was $77.0 Mil.
Long-Term Debt & Capital Lease Obligation was $80.4 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(14.749 / 150.858) / (8.672 / 49.759)
=0.097767 / 0.17428
=0.561

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(49.759 / 49.759) / (150.858 / 150.858)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (250.704 + 36.42) / 293.577) / (1 - (252.664 + 42.953) / 302.252)
=0.021981 / 0.021952
=1.0013

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=150.858 / 49.759
=3.0318

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(5.534 / (5.534 + 42.953)) / (5.483 / (5.483 + 36.42))
=0.114134 / 0.13085
=0.8723

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(40.931 / 150.858) / (37.943 / 49.759)
=0.271321 / 0.762535
=0.3558

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((76.642 + 78.269) / 293.577) / ((80.354 + 76.973) / 302.252)
=0.527667 / 0.520516
=1.0137

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-60.759 - 10.858 - -15.023) / 293.577
=-0.192774

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Poseida Therapeutics has a M-score of -1.88 suggests that the company is unlikely to be a manipulator.


Poseida Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Poseida Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Poseida Therapeutics Business Description

Traded in Other Exchanges
Address
9390 Towne Centre Drive, Suite 200, San Diego, CA, USA, 92121
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.
Executives
Mark J Gergen director, officer: President and CBO C/O MIRATI THERAPEUTICS INC., 9393 TOWN CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
John P. Schmid director 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Luke Corning director 614 DAVIS STREET, EVANSTON IL 60201
Marcea Bland Lloyd director 9360 TOWNE CENTRE DRIVE, SUITE 110, SAN DIEGO CA 92121
Charles M Baum director C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Cynthia Collins director 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Rafael Amado director 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Kristin Yarema officer: President, Cell Therapy C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080
Malin Life Sciences Holdings Ltd 10 percent owner 2 HARBOUR SQUARE, CROFTON ROAD, DUN LAOGHAIRE, CO, DUBLIN L2 ----
Eric Ostertag director, 10 percent owner, officer: Chief Executive Officer C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121
Kerry D. Ingalls officer: Chief Operating Officer C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Brent Warner officer: President, Gene Therapy C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Matthew A. Spear officer: Chief Medical Officer C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121
Harry J Leonhardt officer: GC & Chief Compliance Officer C/O HALOZYME THERAPEUTICS, INC., 11388 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121
David Hirsch director C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025